

References

- 1) Akasaka, T., Tanak, M., Yamaguchi, A., Sato, K. (2001) . Typ 11 Topoisomerase Mutations in Fluoroquinolone - Resistant Clinical strains of *Pseudomonas aeruginosa* isolated in 1998 and 1999 : Role of Target Enzyme in Mechanism of Fluoroquinolone Resistance. *Antimicrobiol Agents and chemotherapy*. 45(8),2263-2268.
- 2) Algun, U., Arisoy, A , Gunduz, T., Ozbakkaloglu, B. (2004) . The resistance of *Pseudomonas aeruginosa* strains to fluoroquinolone group of antibiotics. *Indian J Med Microbiol* 22:112-114 .
- 3) Bhatia, R., Ichhpujani, R.(1994). *Essentials of Medical Microbiology*. First edition. Publisher: JYAPEE BROTHERS, New Delhi, India, ch. 4, PP. 405-410.
- 4) Bouza, E., Garcia – Garrolte, F., Cercenato, E., Marin M., Diaz, MS. (1999). *Pseudomonas aeruginosa* : A. survey of resistance in 136 hospital in Spain. *Antimicrob Agents chemother*. 43(4),981-982.
- 5) Brooks, G ., Butel , J ., Morse, S. (2001) . *Medical Microbiology*. Midde East Edition (twenty second edition). Publisher: Librairie du Liban, Lebanon , ch.10, PP. 144-175.
- 6) Bryan, E., Haraphongse, R, Van den Elzen, M. (1976). Gentamicin resistance in clinical isolates of *Pseudomonas aeruginosa* associated with diminished gentamicin accumulation and no detectable enzymatic modification. *J Antibiot (Tokyo)* . 29(7):743-753 .
- 7) Cambau, E. Perani, E., Di, C. Petinon, C., Trias, J., Jarlier, V. (1995). Role of mutation in DNA gyrase genes in ciprofloxacin resistance of *Pseudomonas aeruginosa* susceptible or resistant to imipenem. *Antimicrobial Agents and Chemotherapy*. 39:2248-2252 .
- 8) Carmeli, Y., Troillet, N., Eliopoulos, G., Samore, M. (1999) . Emergence of Antibiotic- Resistant *Pseudomonas aeruginosa*; Comparison of Risks Associated with Different Antipseudomonal Agents. *Antimicrobial Agent and Chemotherapy* . 43,1379-1382.

- 9) Cheesbrough, M. (2000). District laboratory Practice in Tropical countries, Part 2, Low Price Edition. Cambridge University Press, UK, ch. 7.18.20, PP 193-194.
- 10) Cheesbrough, M. (1989) . Medical Laboratory manual for Tropical Countries . Volume 11. UK., ch 34, 36, 42, PP. 29-31, 61-66 , 264-265 .
- 11) Emori, G., Gaynes, P. (1993). An overview of nosocomial Infections, including the role of the Microbiology laboratory . Clin Microbiol Rev, 6(4):428-442 .
- 12) Erdem, B. (1999). *Pseudomonas*. In : Ustacelebi S. Basic Clinl Microbiol . Ankara, Gunes Publication, pp. 551-558.
- 13) Ergin, C., Mutlu, G. (1999). clinical distribution and antibiotic resistance of pseudomonas species . Eastern Journal of Medicine . 4(2):65-69 .
- 14) Fyfe, M., Harris , G., Govan, W., (1984). Revised pyocin typing method for *Pseudomonas aeruginosa*. Journal of Clinical Microbiology 20:47-50 .
- 15) Gavallo JD , Leblance F, Fabre R,(2001). Fourticq-Esqueoute. Survey of the antibiotic sensitivity of *Pseudomonas aeruginosa* in France and the distribution of beta –lactam resistance mechanism. Pathol Biol ; 49(7):534-539.
- 16) Gillespie, S. (1994). Medical Microbiology Illustrated. First edition, printed in France, ch.7, PP. 83-91.
- 17) Govan, W., Nelson, W. (1992) . Microbiology of Lung infection in cystic fibrosis . British Medical Bulletin 48:912-93 .
- 18) Govan, W. (1978). Pyocin typing of *Pseudomonas aeruginosa* In : Bergan, T., Norris, R. (eds) Methods in Microbiology, vol 10. Academic press, London, pp. 61-91 .
- 19) Greenwood, D., Slack, R., Peutherer, J. (2000). Medical Microbiology. Fifteenth edition. Publisher: Churchill Livingstone. Printed in China, part 1.5, PP. 45-56.
- 20) Henwood, C., Livermore, D., James, D., Warner, M. pseudomonas Study Group (2001). Antimicrobiol susceptibility of *pseudomonas*

- aeruginosa* : results of a UK survey and evaluation of the British Society for Antimicrobiol Chemotherapy Disc Susceptibility test . Journal of Antimicrobiol Chemotherapy. 47,789-799 .
- 21) Higgins, G., Fluit, C., Milatovic, D., Verhoef, J. Schmitz, J. (2002). Antimicrobial susceptibility of imipenem – resistant *Pseudomonas aeruginosa*. Journal of Antimicrobial Chemotherapy . 40:299-301 .
 - 22) Hurly, C., Miller, H., Smith , L. (1995) . Mechanism of amikacin resistance in *Pseudomonas aeruginosa* Isolates from patients with cystic fibrosis . Diagn Microbiol infect Disease . 22(4),331-6 .
 - 23) Johnson, A., Ziegler. R., Lukasewycz, O., Hawley, L. (1996). Board Review Series, Microbiology and Immunology . Midde East Edition. Publisher: MASS PUBLISING CO. Egypt, part VII PP. 84-86 .
 - 24) Kelly, OM., Falkiner, R., Keane, T. (1983) . Acetamide Broth for Isolation of *Pseudomonas aeruginosa* from Patients with Cystic Fibrosis. Journal of Clinical Microbiology 17:159 .
 - 25) King, O, Ward, C., Rany , E., (1954) . Two Simple Media for the Demonstration of Pyocyanin and Flourescein, Journal of laboratory and Clinical Medicine 44:303-307.
 - 26) Lei , C., Wang, B., Sun, Y., shen, Y. (2003) . Susceptibility of 570 *Pseudomonas aeruginosa* strains to 11 antimicrobial agents and the mechanism of its resistance to fluoroquinolones , Zhonghua Yi Xue Za Zhi, 83(5), 403-7.
 - 27) Li, X-Z, Livermore, M. Nikaido, H. (1994). Role of efflux pump(s) in intrinsic resistance of *Pseudomonas aeruginosa* : resistance to tetracycline, chloramphenicol and norfloxacin . Antibiotic Agent Chemother . 38(8): 1732-1741 .
 - 28) Livermore, M. (1989). Role of Beta–Lactamase and impermeability in the resistance of *Pseudomonas aeruginosa*. Antibiot chemother. 42:257-263 .
 - 29) Mackie & McCarteny (1996). Practical Medical Microbiology. Edited by : Collee, J.,Fraser,A.,Marmion,B.,Simmons,A. Fourteenth edition. Publisher: Churchill Livingstone UK, ch. 23 , PP. 413-423 .

- 30) Murry, P., Rosenthal, K., Kobayashi, G., Pfaller, M. (2002). Medical Microbiology. Fourth edition. Printed in United State of America, ch. 20 , PP.185-193.
- 31) NCCLS (1997).Performance standards for Antimicrobial disk Susceptibility tests – Six edition, 1997. ISBN 1 56238 306 6. Available from NCCLS. 940 West Valley Road. Suit 1400. Wayne. PA 19087-1898, USA .
- 32) Norrby, R., Finch, G., Glauser, M. and a Ureapean Study Group (1993). Monotherapy in serious hospital-acquired Infections : a clinical trial of ceftazidime versus imipenem / cilastrin . Journal of Antimicrobial Chemotherapy 31:927-937.
- 33) Ogle, W., Janda, M., Woods, E., Vasil, L. (1987). Characterization and use of a DNA probe as an epidemiological marker for *Pseudomonas aeruginosa*. Journal of Infectious Disease 155:119127.
- 34) Philips, I. (1969), Identification of *Pseudomonas aeruginosa* in the clinical laboratory. Journal of Medical Microbiology 2 : 9-16.
- 35) Pitt., L. (1988), Epidemiological typing of *Pseudomonas aeruginosa*. European Journal of Clinical Microbiology, and infectous Disease 7:238-247.
- 36) Prince, A. (1986). Antibiotic resistance of *Pseudomonas aeruginosa* species . J pediatr . 108:830-834.
- 37) Sader, S. (2000). Antimicrobial resistance in Brazil : comparison of results from two multicentre Studies . BJID . 4,91-99 .
- 38) Shahid, M., Malik, A. (2004). Plasmid mediated amikacin resistance in clinical isolates of *Pseudomonas aeruginosa* . Indian J Med Microbiol . 22:182-184.
- 39) Shawar, R., Macleod, D., Garber R., Burns, J., stapp, J., Clausen , C., Tanaka, K. (1999). Activities of Tobramycin and Six Other Antibiotics against *Pseudomonas aeruginosa*. Antimicrobial Agents and chemotherapy. 43(12), 2877-1880 .

- 40) Smith, W., Hirst, H., Hughes, K., Gensburg, K. Govan, W. (1992). The pyocin sa receptor of *Pseudomonas aeruginosa* in associated with ferripyochelin uptake. Journal of Bacteriology 174:4847-4849.
- 41) Strophi, W., Rouse, H., Fisher, B. (2001). Lippincott's Illustrated Reviews. Microbiology, United States of America, ch.5, PP. 35-50
- 42) Tunger, O., Aydemir, S. (2000). Quinolones. Turk J Antibiotics. 1, 18-24.
- 43) WHO,(1996).Guideline for antimicrobial resistance Surveillance, ISBN 92 9021 2136. Available from WHO Regional Office for the Eastern Mediterranean. PO Box 151. Alexandria 21511. Egypt.